Imunon, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31)
Imunon, Inc. (IMNN) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) of $126.61 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2014-03-13.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses · last filed 2014-03-13
- Imunon, Inc. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2012 was $126.61K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|
| 2012-12-31 | $126.61K 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |